Abstract 532P
Background
Immune checkpoint inhibitors (ICIs) have come to be used for the treatment of the patients with malignant pleural mesothelioma (MPM). Although modified RECIST (mRECIST) criteria is the standard method to evaluate the antitumor efficacy of ICIs, it is sometimes difficult to distinguish progressive disease from pseudoprogression (PsPD). While serum soluble mesothelin related peptide (SMRP) is commonly known as a specific tumor marker of MPM, the significance of SMRP levels in determining the efficacy of ICI treatment has not been established.
Methods
We investigated the relationship between changes of serum SMRP levels and treatment response in MPM patients treated with ipilimumab plus nivolumab combination therapy at our hospital between June 2021 and January 2023.
Results
Twenty-eight patients were included in the study. Median age was 75 years (59-85). The number of histological subtypes of epithelioid, sarcomatoid, biphasic and desmoplastic were 18, 6, 3 and 1, respectively. Treatment response was evaluated by mRECIST. The number of patients who achieved partial response (PR), stable disease (SD) and progressive disease (PD) were 9, 16 and 3, respectively. Among 25 patients with PR and SD, PsPD was observed in 5 patients (PR/SD: 3/2). The median serum SMRP before treatment in all patients was 0.90 nmol/L (0.4 - 16.9)., and the change from baseline at the time of first evaluation was +0.1 nmol/L (-4.5 - +24.5), The median change of serum SMRP level from baseline in patients with PR, SD, PsPD and PD was 0.0 nmol/L (-1.0 - +1.4), +0.1 nmol/L (-4.5 - +4.5), +0.2 nmol/L (-0.9 - +0.9) and +19.5 nmol/L (+0.1 - +24.5), respectively. These results indicated that serum SMRP level in patients with PD already tended to increase at the time of first evaluation.
Conclusions
Our results suggested that changes in serum SMRP levels was useful in determining the efficacy of ICI treatment. We are planning to accumulate more cases in the future for further investigation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
613P - Differences in the interactions with pharmaceutical companies between medical oncologists and infectious diseases physicians
Presenter: Hui Ling Yeoh
Session: Poster Display
Resources:
Abstract
614P - The role of PD-L1 expression in prognosis of osteosarcoma patients: A systematic review and meta-analysis
Presenter: Alexander Purnomo
Session: Poster Display
Resources:
Abstract
615P - Pulmonary resectable metastases of osteosarcoma with apatinib and chemotherapy (PROACH): An open-label, single-arm phase II clinical trial
Presenter: Qiyuan Bao
Session: Poster Display
Resources:
Abstract
616P - Incidence of cardiotoxicity after high cumulative dose of anthracyclines in adult patients with advanced soft tissue sarcomas: A systematic review and meta-analysis
Presenter: Paula Franco
Session: Poster Display
Resources:
Abstract
617P - The risk of acute myeloid leukaemia in patients with Ewing's sarcoma and trend analysis: A SEER-based study 2000-2020
Presenter: Mohamed Abdalla
Session: Poster Display
Resources:
Abstract
618P - Adult renal Ewing’s sarcoma/primitive neuroectodermal tumor: A 20-year retrospective review of molecular histopathological profiles, and clinical outcomes
Presenter: Josh Thomas Georgy
Session: Poster Display
Resources:
Abstract
619P - Single-cell and bulk RNA-seq analyses decode the renal microenvironment induced by polystyrene microplastics in mice receiving high-fat diet
Presenter: Wangrui Liu
Session: Poster Display
Resources:
Abstract
620P - A unique circulating microRNA pairs signature serves as a superior tool for early diagnosis of pan-cancer
Presenter: Dongyu Li
Session: Poster Display
Resources:
Abstract
621P - Effective identification of primary liver cancer from cirrhosis or chronic hepatitis virus infection using eight methylated plasma DNA markers: Marker discovery, phase I pilot, and phase II clinical validation
Presenter: Tian Yang
Session: Poster Display
Resources:
Abstract
622P - A prognostic and immune infiltration analysis of CCL26 in pan-cancer
Presenter: Mengyue Li
Session: Poster Display
Resources:
Abstract